Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 6/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.41 |
| ▸ | PDE8B | O95263 | 2/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | PDE8A | O60658 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15081949 | 1.00 | TSHR (0.44) | TSHRALDH1A1CYP2C9CYP3A4CYP2D6 | |
| SCHEMBL13676575 | 0.92 | ALOX15 (0.44) | TSHRALDH1A1CYP2C9CYP3A4CYP2D6 | |
| SCHEMBL15084367 | 0.82 | LMNA (0.52) | TSHRALDH1A1CYP2C9CYP3A4CYP2D6 | |
| SCHEMBL19381825 | 0.82 | LMNA (0.52) | TSHRALDH1A1CYP2C9CYP3A4CYP2D6 | |
| SCHEMBL15081950 | 0.76 | ALDH1A1 (0.57) | ALDH1A1MAPK1 | |
| SCHEMBL4487346 | 0.76 | ALOX15 (0.59) | TSHRALDH1A1CYP2C9CYP3A4CYP2D6 | |
| SCHEMBL807362 | 0.74 | ALOX15 (0.58) | TSHRALDH1A1CYP2C9CYP3A4CYP2D6 | |
| SCHEMBL13741194 | 0.73 | PKM (0.49) | ALDH1A1CYP2C9CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL19844811 | 0.73 | ALOX15 (0.54) | ALDH1A1ALOX15 | |
| SCHEMBL19844814 | 0.73 | ALOX15 (0.54) | ALDH1A1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9884048-B2 | ERK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2018-02-06 | — | — | US | disclosed |
| US-20170266167-A1 | ERK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170266167-A1 | ERK INHIBITORS | MAPK1, MAPK3, MAPK6 | TSHR 3446/4885ALDH1A1 670/4885CYP2C9 678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.